Abstract:Introduction: Growing evidence suggests a link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded RV, and mortality in pulmonary arterial hypertension (PAH). However, there are no currently available therapies that specifically target RV fibrosis. Using RV tissues from a preclinical rat PAH model, we previously reported that activation of stress-responsive protein kinase D (PKD) and phosphorylation of its substrate dynamin-related protein 1 (DRP1) occur specifically at the outer mitochondrial membrane (OMM) of RV cardiac fibroblasts (RV-CFs), but not in RV myocytes. RV-CFs isolated from PAH rats exhibited increased mitochondrial fission, mitochondrial reactive oxygen species (mROS), and proliferative signaling compared to RV-CFs from control animals, suggesting an association between PKD signaling in RV-CFs and RV fibrosis. Hypothesis: Inhibition of mitochondrial PKD signaling in CFs can attenuate RV fibrosis in PAH. Methods: Primary adult CFs from human ventricles were used for in vitro assays. A preclinical rat PAH model (Sugen 5416 injection and 3-week hypoxia followed by 4-week normoxia) was used for in vivo assays. Results: To specifically inhibit PKD activity at the OMM, an OMM-targeted dominant-negative PKD1 (mt-PKD-DN) was generated by adding an OMM-target sequence (amino acid 1-33 from human TOM20) at the N-terminus of PKD1-K612W. We confirmed that mt-PKD-DN is specifically expressed in mitochondria and decreases basal PKD activity only in mitochondria, assessed by protein fractionation. Importantly, mt-PKD-DN was able to inhibit mitochondrial fission, reduce mROS, hyperpolarize mitochondrial membrane potential, and ultimately decrease CF proliferation in vitro. To inhibit mitochondrial PKD activity in quiescent and resident CFs in vivo, we next administrated CF-selective adeno-associated virus serotype 9 (AAV9) carrying human TCF21 (hTCF21) promoter and mt-PKD-DN into the rat PAH model by tail vein injection. Introduction of AAV9-hTCF21-mt-PKD-DN or its control virus did not significantly alter baseline cardiac function. CF-specific mt-PKD-DN expression was able to significantly reduce RV hypertrophy/fibrosis, and RV-CF hyperproliferation as assessed by immunostaining of a nucleus-localized marker of active cell proliferation Ki67. Lastly, we found the partial recovery of in vivo RV function (i.e., recovery of tricuspid annular plane systolic excursion in echocardiography) in PAH rats with mt-PKD-DN. Conclusion: Targeting mitochondrial PKD may be a potential therapeutic strategy to reduce cardiac fibrosis under pathological conditions including PAH. R01HL136757 (to J.O.-U), AHA 18CDA34110091 (to B.S.J) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response

Mechanisms underlying age-associated exacerbation of pulmonary veno-occlusive disease

Depletion of Protein Phosphatase 1 Results in Persistent Activation of the Integrated Stress Response and Age-Associated Exacerbation of Pulmonary Veno-Occlusive Disease

PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension

GCN2 Regulates ATF3-p38 MAPK Signaling Transduction in Pulmonary Veno-Occlusive Disease

Rapid disease progress in a PVOD patient carrying a novel EIF 2 AK 4 mutation: a case report

Mitomycin C induces pulmonary vascular endothelial‐to‐mesenchymal transition and pulmonary veno‐occlusive disease via Smad3‐dependent pathway in rats

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension

Reversal of Inflammatory Reprogramming by Vasodilator Agents in Pulmonary Hypertension

Role of mitochondrial PKD on right ventricular fibrosis under pulmonary hypertension

Rapid disease progress in a PVOD patient carrying a novel EIF<sub>2</sub>AK<sub>4</sub>mutation: a case report

Insights into the Molecular Mechanism of Pulmonary Vein Stenosis in Pediatric Patients

Abstract 17370: Activation of Endothelial GCN2 Kinase Contributes to Pulmonary Vascular Remodeling and Pulmonary Arterial Hypertension

Abstract 14033: Inhibition of the Prolyl Isomerase Pin1 Improves Endothelial Function and Attenuates Vascular Remodelling in Pulmonary Hypertension by Inhibiting TGF-β Signalling

PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Differential Expression Profile of microRNAs and Tight Junction in the Lung Tissues of Rat With Mitomycin-C-Induced Pulmonary Veno-Occlusive Disease

Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension

Abstract 12497: Diminished Cavolin-1 Expression and Augmented Nitrative Stress Secondary to Prolyl-4 Hydroxylase 2 Deficiency Contribute to Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension

Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease

Genetic regulation and targeted reversal of lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension